Pay in 4 interest-free payments of $6.47 Learn more
Ships within 48 hours · Estimated delivery Sep 3 - Sep 8
Oral GLP-1s for obesity saw a recent setback when in April (April 2025), Pfizer announced that it was discontinuing development of danuglipron, an oral GLP-1 receptor agonist, which was being investigated for chronic weight management, due to potential liver toxicity
Retinol-based body treatments work by accelerating cell turnover, helping tanned cells shed faster
The Data on Regain Studies following Tirzepatide discontinuation show that participants regain approximately two-thirds of their lost weight within one year of stopping
An injectable TME-responsive nanocomposite hydrogel incorporating IL11R-targeted liposomes has also been developed for local delivery of cisplatin-loaded MnO2 along with a MYC inhibitor, enabling sustained drug release and reshaping of the immune microenvironment in MYC-amplified osteosarcoma (45)
US$ 23.83
US$ 26.59
US$ 21.47
US$ 20.54
US$ 25.66
US$ 20.88
US$ 24.54
US$ 29.11
